Hepatitis C Treatment Options - Vertex study drug beats back Hep. C

Vertex study drug beats back Hep. C
United Press International - Jan 9, 2006CAMBRIDGE, Mass., Jan. 9 (UPI) -- Vertex said Monday its protease inhibitor VX-950 used with standard therapy dramatically cuts hepatitis C (HCV) viral loads. ...

Median 5.5 log10 reduction in HCV RNA achieved in patients ...
Oxfordshire Bioscience Network (press release), UK - Jan 9, 2006... data announced today by Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) show that VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor ...

Chiron partners with Portland's AVI
San Francisco Business Times, CA - Jan 30, 2006... license to Chiron's patents and patent applications for the research, development and commercialization of drugs that fight the hepatitis C virus (HCV). ...